289 related articles for article (PubMed ID: 37771588)
1. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.
Tsai YG; Liao PF; Hsiao KH; Wu HM; Lin CY; Yang KD
Front Immunol; 2023; 14():1230264. PubMed ID: 37771588
[TBL] [Abstract][Full Text] [Related]
2. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
von Spee-Mayer C; Siegert E; Abdirama D; Rose A; Klaus A; Alexander T; Enghard P; Sawitzki B; Hiepe F; Radbruch A; Burmester GR; Riemekasten G; Humrich JY
Ann Rheum Dis; 2016 Jul; 75(7):1407-15. PubMed ID: 26324847
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients.
Schaier M; Gottschalk C; Uhlmann L; Speer C; Kälble F; Eckstein V; Müller-Tidow C; Meuer S; Mahnke K; Lorenz HM; Zeier M; Steinborn A
Arthritis Res Ther; 2018 Dec; 20(1):278. PubMed ID: 30563559
[TBL] [Abstract][Full Text] [Related]
4. CD4
Peixoto TV; Carrasco S; Botte DAC; Catanozi S; Parra ER; Lima TM; Ugriumov N; Soriano FG; de Mello SBV; Rodrigues CM; Goldenstein-Schainberg C
Adv Rheumatol; 2019 Jul; 59(1):30. PubMed ID: 31340848
[TBL] [Abstract][Full Text] [Related]
5. Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection.
Zhang JQ; Zhang SX; Wang J; Qiao J; Qiu MT; Wu XY; Chen JW; Gao C; Li XF
Curr Med Res Opin; 2022 Jun; 38(6):1037-1044. PubMed ID: 35414310
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus.
Terrier B; Costedoat-Chalumeau N; Garrido M; Geri G; Rosenzwajg M; Musset L; Klatzmann D; Saadoun D; Cacoub P
J Rheumatol; 2012 Sep; 39(9):1819-28. PubMed ID: 22859347
[TBL] [Abstract][Full Text] [Related]
7. IL-6 alters migration capacity of CD4
He S; Xue M; Cai G
Scand J Immunol; 2021 Nov; 94(5):e13099. PubMed ID: 34940981
[TBL] [Abstract][Full Text] [Related]
8. Phenotypical changes and clinical significance of CD4
Yuan S; Zeng Y; Li J; Wang C; Li W; He Z; Ye J; Li F; Chen Y; Lin X; Yu N; Cai X
Lupus Sci Med; 2022 Jun; 9(1):. PubMed ID: 35732344
[TBL] [Abstract][Full Text] [Related]
9. IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.
Rose A; von Spee-Mayer C; Kloke L; Wu K; Kühl A; Enghard P; Burmester GR; Riemekasten G; Humrich JY
Cells; 2019 Oct; 8(10):. PubMed ID: 31614462
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
Lyu MA; Tang X; Khoury JD; Raso MG; Huang M; Zeng K; Nishimoto M; Ma H; Sadeghi T; Flowers CR; Parmar S
Front Immunol; 2023; 14():1217121. PubMed ID: 37736101
[TBL] [Abstract][Full Text] [Related]
11. Analysis of FOXP3
Schmidt A; Rieger CC; Venigalla RK; Éliás S; Max R; Lorenz HM; Gröne HJ; Krammer PH; Kuhn A
Immunol Res; 2017 Apr; 65(2):551-563. PubMed ID: 28224362
[TBL] [Abstract][Full Text] [Related]
12. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
Mizui M; Tsokos GC
Front Immunol; 2018; 9():786. PubMed ID: 29755456
[TBL] [Abstract][Full Text] [Related]
13. Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives.
Costa N; Marques O; Godinho SI; Carvalho C; Leal B; Figueiredo AM; Vasconcelos C; Marinho A; Moraes-Fontes MF; Gomes da Costa A; Ponte C; Campanilho-Marques R; Cóias T; Martins AR; Viana JF; Lima M; Martins B; Fesel C
Clin Exp Immunol; 2017 Sep; 189(3):318-330. PubMed ID: 28542701
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells in patients with systemic lupus erythematosus.
Alvarado-Sánchez B; Hernández-Castro B; Portales-Pérez D; Baranda L; Layseca-Espinosa E; Abud-Mendoza C; Cubillas-Tejeda AC; González-Amaro R
J Autoimmun; 2006 Sep; 27(2):110-8. PubMed ID: 16890406
[TBL] [Abstract][Full Text] [Related]
15. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
He J; Zhang X; Wei Y; Sun X; Chen Y; Deng J; Jin Y; Gan Y; Hu X; Jia R; Xu C; Hou Z; Leong YA; Zhu L; Feng J; An Y; Jia Y; Li C; Liu X; Ye H; Ren L; Li R; Yao H; Li Y; Chen S; Zhang X; Su Y; Guo J; Shen N; Morand EF; Yu D; Li Z
Nat Med; 2016 Sep; 22(9):991-3. PubMed ID: 27500725
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.
Horwitz DA; Bickerton S; Koss M; Fahmy TM; La Cava A
Arthritis Rheumatol; 2019 Apr; 71(4):632-640. PubMed ID: 30407752
[TBL] [Abstract][Full Text] [Related]
17. Imbalance between CD8
Minning S; Xiaofan Y; Anqi X; Bingjie G; Dinglei S; Mingshun Z; Juan X; Xiaohui J; Huijuan W
Lupus; 2019 Sep; 28(10):1214-1223. PubMed ID: 31399013
[TBL] [Abstract][Full Text] [Related]
18. Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease.
Nasa Y; Satake A; Tsuji R; Saito R; Tsubokura Y; Yoshimura H; Ito T
Front Immunol; 2024; 15():1326066. PubMed ID: 38665907
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
20. Increased interleukin-23 receptor(+) T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Puwipirom H; Hirankarn N; Sodsai P; Avihingsanon Y; Wongpiyabovorn J; Palaga T
Arthritis Res Ther; 2010; 12(6):R215. PubMed ID: 21110900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
